Progression-free survival at 2 years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma

Cancer Medicine
A Jiménez-UbietoGELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) cooperative study group

Abstract

Overall survival (OS) is the gold-standard end point for studies evaluating autologous stem cell transplantation (ASCT) in follicular lymphoma (FL), but assessment may be elusive due to the lengthy disease course. We analyzed the validity of two earlier end points, proposed in the setting of first-line chemo-/immunotherapy, as surrogates for OS-progression-free survival (PFS) status at 24 months (PFS24) and complete response at 30 months (CR30) post-ASCT. We also have investigated the clinical features of patients with early progression after ASCT. Data were available for 626 chemosensitive FL patients who received ASCT between 1989 and 2007. Median follow-up was 12.2 years from ASCT. In the PFS24 analysis, 153 (24%) patients progressed within 24 months and 447 were alive and progression-free at 24 months post-ASCT (26 who died without disease progressions within 24 months were excluded). Early progression was associated with shorter OS (hazard ratio [HR], 6.8; P = 0.00001). In the subgroup of patients who received an ASCT in the setting or relapse after being exposed to rituximab, the HR was 11.3 (95% CI, 3.9-30.2; P < 0.00001). In the CR30 analysis, 183 of 596 (31%) response-evaluable patients progressed/died with 30 months p...Continue Reading

References

Jan 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P W JohnsonT A Lister
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
Apr 21, 2001·Bone Marrow Transplantation·A SalarUNKNOWN GEL/TAMO Spanish Cooperative Group
Dec 19, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M D CaballeroE Conde
Oct 1, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harry C SchoutenGunnar Kvalheim
Jun 29, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wade T SwensonBrian K Link
Apr 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Qi LiuPeter McLaughlin
Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Harmonization Project on Lymphoma
Jul 21, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Mitchell SabloffLothar B Huebsch
Jan 31, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M KornackerP Dreger
Sep 29, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Catherine ThieblemontChristian Gisselbrecht
Nov 2, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marc BuyseEverardo D Saad
Jan 7, 2014·Cell Reports·Laura PasqualucciRiccardo Dalla-Favera
Jul 1, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carla CasuloJonathan W Friedberg
Oct 21, 2016·American Journal of Hematology·Matthew J MaurerBrian K Link
Dec 29, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Qian ShiDaniel J Sargent

❮ Previous
Next ❯

Citations

Aug 22, 2018·Hematological Oncology·Ana Jiménez-UbietoUNKNOWN GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) Cooperative Study Group
Feb 23, 2019·British Journal of Haematology·Laura MagnanoUNKNOWN Grupo Español de Linfomas y Trasplante Autólogo de Médula Ósea (GELTAMO)
Nov 9, 2019·Hematological Oncology·Kitsada WudhikarnUNKNOWN Thai Lymphoma Study Group

❮ Previous
Next ❯

Software Mentioned

GELTAMO

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.